风湿免疫科指南

订阅

MedSci主页 / 所有栏目 / 风湿免疫科指南

中药新药用于类风湿关节炎临床研究技术指导原则

2019-10-31 国家药品监督管理局药品审评中心（CDE）

类风湿关节炎

中药新药用于类风湿关节炎临床研究技术指导原则

中文标题：

中药新药用于类风湿关节炎临床研究技术指导原则

发布机构：

国家药品监督管理局药品审评中心（CDE）

发布日期：

2019-10-31

简要介绍：

中药新药用于类风湿关节炎临床研究技术指导原则

相关资料下载：
[AttachmentFileName(sort=100, fileName=中药新药用于类风湿关节炎临床研究技术指导原则)] GetToolGuiderByIdResponse(projectId=1, id=e0ecc1c0018132c8, title=中药新药用于类风湿关节炎临床研究技术指导原则, enTitle=, guiderFrom=, authorId=null, author=, summary=中药新药用于类风湿关节炎临床研究技术指导原则, cover=, journalId=null, articlesId=null, associationId=1936, associationName=国家药品监督管理局药品审评中心（CDE）, associationIntro=国家药品监督管理局药品审评中心（CDE）, copyright=0, guiderPublishedTime=Thu Oct 31 04:40:39 CST 2019, originalUrl=, linkOutUrl=, content=中药新药用于类风湿关节炎临床研究技术指导原则, tagList=[TagDto(tagId=457, tagName=类风湿关节炎)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=37, categoryName=中医科, tenant=100), CategoryDto(categoryId=67, categoryName=研究设计与统计, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3262, appHits=292, showAppHits=2, pcHits=1615, showPcHits=2396, likes=45, shares=16, comments=8, approvalStatus=1, publishedTime=Thu Oct 31 04:40:39 CST 2019, publishedTimeString=2019-10-31, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=fbzhang, createdTime=Thu Oct 31 04:40:39 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 12:27:20 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=中药新药用于类风湿关节炎临床研究技术指导原则)])
中药新药用于类风湿关节炎临床研究技术指导原则
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1234812, encodeId=b0d112348124f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ca52621701, createdName=lywyz2, createdTime=Tue Jul 26 10:09:13 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187853, encodeId=a90b118e853f3, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Mon Jan 24 22:34:25 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011497, encodeId=423d101149eec, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d083964238, createdName=1395e30cm10暂无昵称, createdTime=Wed Aug 25 21:33:38 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973433, encodeId=5e7d9e34339c, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91111899745, createdName=ms8864469033539732, createdTime=Mon Jun 14 12:43:02 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967716, encodeId=db5f96e71699, content=下到了 谢谢 但是有2017版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210522/4ccccc7957ca4b7db4849661f2ab11de/25ad835c2ec14ae78ad4b112fae2f7b8.jpg, createdBy=05de5506029, createdName=比奇堡鱼, createdTime=Sat May 22 13:23:08 CST 2021, time=2021-05-22, status=1, ipAttribution=)]
    2022-07-26 lywyz2

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1234812, encodeId=b0d112348124f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ca52621701, createdName=lywyz2, createdTime=Tue Jul 26 10:09:13 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187853, encodeId=a90b118e853f3, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Mon Jan 24 22:34:25 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011497, encodeId=423d101149eec, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d083964238, createdName=1395e30cm10暂无昵称, createdTime=Wed Aug 25 21:33:38 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973433, encodeId=5e7d9e34339c, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91111899745, createdName=ms8864469033539732, createdTime=Mon Jun 14 12:43:02 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967716, encodeId=db5f96e71699, content=下到了 谢谢 但是有2017版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210522/4ccccc7957ca4b7db4849661f2ab11de/25ad835c2ec14ae78ad4b112fae2f7b8.jpg, createdBy=05de5506029, createdName=比奇堡鱼, createdTime=Sat May 22 13:23:08 CST 2021, time=2021-05-22, status=1, ipAttribution=)]
    2022-01-24 ms3000000637975859

    实用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1234812, encodeId=b0d112348124f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ca52621701, createdName=lywyz2, createdTime=Tue Jul 26 10:09:13 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187853, encodeId=a90b118e853f3, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Mon Jan 24 22:34:25 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011497, encodeId=423d101149eec, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d083964238, createdName=1395e30cm10暂无昵称, createdTime=Wed Aug 25 21:33:38 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973433, encodeId=5e7d9e34339c, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91111899745, createdName=ms8864469033539732, createdTime=Mon Jun 14 12:43:02 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967716, encodeId=db5f96e71699, content=下到了 谢谢 但是有2017版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210522/4ccccc7957ca4b7db4849661f2ab11de/25ad835c2ec14ae78ad4b112fae2f7b8.jpg, createdBy=05de5506029, createdName=比奇堡鱼, createdTime=Sat May 22 13:23:08 CST 2021, time=2021-05-22, status=1, ipAttribution=)]
    2021-08-25 1395e30cm10暂无昵称

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1234812, encodeId=b0d112348124f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ca52621701, createdName=lywyz2, createdTime=Tue Jul 26 10:09:13 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187853, encodeId=a90b118e853f3, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Mon Jan 24 22:34:25 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011497, encodeId=423d101149eec, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d083964238, createdName=1395e30cm10暂无昵称, createdTime=Wed Aug 25 21:33:38 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973433, encodeId=5e7d9e34339c, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91111899745, createdName=ms8864469033539732, createdTime=Mon Jun 14 12:43:02 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967716, encodeId=db5f96e71699, content=下到了 谢谢 但是有2017版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210522/4ccccc7957ca4b7db4849661f2ab11de/25ad835c2ec14ae78ad4b112fae2f7b8.jpg, createdBy=05de5506029, createdName=比奇堡鱼, createdTime=Sat May 22 13:23:08 CST 2021, time=2021-05-22, status=1, ipAttribution=)]
    2021-06-14 ms8864469033539732

    实用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1234812, encodeId=b0d112348124f, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6ca52621701, createdName=lywyz2, createdTime=Tue Jul 26 10:09:13 CST 2022, time=2022-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187853, encodeId=a90b118e853f3, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=89ae6481716, createdName=ms3000000637975859, createdTime=Mon Jan 24 22:34:25 CST 2022, time=2022-01-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1011497, encodeId=423d101149eec, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5d083964238, createdName=1395e30cm10暂无昵称, createdTime=Wed Aug 25 21:33:38 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=973433, encodeId=5e7d9e34339c, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=91111899745, createdName=ms8864469033539732, createdTime=Mon Jun 14 12:43:02 CST 2021, time=2021-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967716, encodeId=db5f96e71699, content=下到了 谢谢 但是有2017版吗, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210522/4ccccc7957ca4b7db4849661f2ab11de/25ad835c2ec14ae78ad4b112fae2f7b8.jpg, createdBy=05de5506029, createdName=比奇堡鱼, createdTime=Sat May 22 13:23:08 CST 2021, time=2021-05-22, status=1, ipAttribution=)]
    2021-05-22 比奇堡鱼

    下到了 谢谢 但是有2017版吗

    0

相关指南

类风湿关节炎病证结合诊疗指南

中华中医药学会(CACM,China Association of Chinese Medcine) 风湿病分会 · 2018-10-20

中国类风湿关节炎患者报告的临床结局量表专家共识

中华中医药学会(CACM,China Association of Chinese Medcine) 风湿病分会 · 2018-05-20

2018中国类风湿关节炎诊疗指南

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2018-04-05

2016 EULAR建议：类风湿性关节炎以及其他形式的炎症性关节病患者心血管疾病风险的管理  

欧洲抗风湿病联盟(EULAR,The European League Against Rheumatism) · 2016-10-03

2014 类风湿关节炎患者的慢病管理专家共识

中国风湿免疫科相关专家小组（统称） · 2016-02-29

风湿免疫疾病( 类风湿关节炎) 超药品说明书用药专家共识

广东省药学会 · 2014-09-25